“We expect the IRA to negatively impact sales and profits and may lead to further political pressure, or legislative, regulatory, or other efforts to introduce lower prices reduce spending on the Medicare and Medicaid programs expand and strengthen the affordable care act and lower, the overall spending by the government and prescription medicines. In addition, various state legislature and regulators have an acted or pursuing policy changes that could further increase pricing pressure on our products as a result we expect the healthcare industry in the US will continue to be subject to increase pricing and spending pressure.”
